Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Revenues Down, Net Loss Up

NEW YORK, Feb. 26 -- Lynx Therapeutics recorded a net loss of $3 million for the fourth quarter ending Dec. 31, the company reported today.

The Hayward, Calif.-based genomics discovery services firm increased its losses from $2.8 million for the year-ago quarter and had total revenues of $4.7 million for the quarter, compared to $5.7 million for the same quarter in 2001. The company had net revenues of $4.8 million for the third quarter of 2002 and a net loss of $3.3 million. Lynx spent $4.2 million on research and development for the quarter, compared to $6.2 million for the year-ago quarter.

Lynx laid off 30 employees in January, following a layoff of 44 employees in April, leaving the company with a headcount of 90. The layoffs cost the company about $500,000.

Going forward, the firm is focusing on increasing its revenues, Kevin Corcoran, Lynx CEO and president said in a statement. The company sells analysis services using its massively parallel signature sequencing (MPSS) technology.

The company is estimating positive-operating results for fiscal year 2003, and revenues in a range of $24 million to $27 million.

The company reported cash and cash equivalents of $11.7 million as of Dec. 31.

For more information, click here .

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.